Mitsubishi UFJ Asset Management Co. Ltd. Cuts Position in Thermo Fisher Scientific Inc. $TMO

Mitsubishi UFJ Asset Management Co. Ltd. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,086,025 shares of the medical research company’s stock after selling 92,094 shares during the quarter. Thermo Fisher Scientific makes up about 0.8% of Mitsubishi UFJ Asset Management Co. Ltd.’s holdings, making the stock its 16th biggest holding. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Thermo Fisher Scientific were worth $1,235,991,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TMO. Wellington Management Group LLP grew its stake in shares of Thermo Fisher Scientific by 88.9% during the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock worth $1,309,292,000 after purchasing an additional 1,270,191 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Thermo Fisher Scientific by 54.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock worth $1,732,422,000 after buying an additional 1,262,967 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Thermo Fisher Scientific by 21.0% during the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock worth $2,874,069,000 after acquiring an additional 1,028,125 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Thermo Fisher Scientific by 89.1% in the 2nd quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock valued at $720,576,000 after acquiring an additional 825,649 shares during the last quarter. Finally, Capital World Investors lifted its stake in Thermo Fisher Scientific by 7.4% during the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, Citigroup upped their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $623.05.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,800 shares of company stock valued at $2,963,544 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $466.74 on Wednesday. The stock’s 50-day moving average price is $495.23 and its 200 day moving average price is $547.61. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $173.45 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 2.05 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period last year, the business posted $5.15 EPS. The company’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.